GlassScriptPhysician profile
Terinell Beaver
NPI 1215030820
$1,802.84
in general payments reported to CMS, 2019-2025
16 companies · $45.02 in 2025
The $45.02 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,168 · 2020: $195 · 2022: $264 · 2023: $88.39 · 2024: $42.00 · 2025: $45.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $436.53 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $319.46 | 2019-2023 | |
| Abbott Laboratories | $228.70 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $221.74 | 2019-2020 | |
| Astellas Pharma US INC | $165.22 | 2019-2020 | |
| Pfizer INC. | $95.69 | 2019-2022 | |
| Amgen INC. | $79.16 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $61.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $45.82 | 2019-2020 | |
| Abbvie INC. | $31.77 | 2019-2022 | |
| Allergan, INC. | $28.49 | 2019 | |
| Amarin Pharma, INC. | $26.66 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.30 | 2019-2020 | |
| Eisai INC. | $13.01 | 2019 | |
| Genentech USA, INC. | $12.53 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terinell Beaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.